Abstract
Colorectal cancer (CRC) is one of the leading causes of cancer death in the United States. Research has led to an explosion of knowledge into the molecular basis of CRC in the past decades. Numerous receptors and intracellular proteins have been identified and implicated in the growth and progression of metastatic CRC, thus creating novel targets for drug development. Many agents are under development and have begun to enter early and even later-stage clinical trials. Results of these agents have demonstrated some encouraging activity but in a small number of patients. Research into predictive biomarkers aims to select the patients who may benefit from these novel agents. This review will address several of these promising new agents, their potential relevance to CRC, results from early clinical studies, and their incorporation into future and ongoing CRC clinical trials. Clearly, there is an urgent need for new agents in this disease, but as we learned from the experience with epidermal growth factor receptor-targeted antibodies, patient selection will be increasingly be required for individualized therapy to become a reality in CRC.
| Original language | English |
|---|---|
| Pages (from-to) | 273-282 |
| Number of pages | 10 |
| Journal | Cancer Journal |
| Volume | 16 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2010 May 1 |
| Externally published | Yes |
Fingerprint
Keywords
- Metastatic colorectal cancer
- Novel agents
- Targeted agents
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Novel agents in the treatment of metastatic colorectal cancer. / Leong, Stephen; Messersmith, Wells A.; Tan, Aik-Choon; Eckhardt, S. Gail.
In: Cancer Journal, Vol. 16, No. 3, 01.05.2010, p. 273-282.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Novel agents in the treatment of metastatic colorectal cancer
AU - Leong, Stephen
AU - Messersmith, Wells A.
AU - Tan, Aik-Choon
AU - Eckhardt, S. Gail
PY - 2010/5/1
Y1 - 2010/5/1
N2 - Colorectal cancer (CRC) is one of the leading causes of cancer death in the United States. Research has led to an explosion of knowledge into the molecular basis of CRC in the past decades. Numerous receptors and intracellular proteins have been identified and implicated in the growth and progression of metastatic CRC, thus creating novel targets for drug development. Many agents are under development and have begun to enter early and even later-stage clinical trials. Results of these agents have demonstrated some encouraging activity but in a small number of patients. Research into predictive biomarkers aims to select the patients who may benefit from these novel agents. This review will address several of these promising new agents, their potential relevance to CRC, results from early clinical studies, and their incorporation into future and ongoing CRC clinical trials. Clearly, there is an urgent need for new agents in this disease, but as we learned from the experience with epidermal growth factor receptor-targeted antibodies, patient selection will be increasingly be required for individualized therapy to become a reality in CRC.
AB - Colorectal cancer (CRC) is one of the leading causes of cancer death in the United States. Research has led to an explosion of knowledge into the molecular basis of CRC in the past decades. Numerous receptors and intracellular proteins have been identified and implicated in the growth and progression of metastatic CRC, thus creating novel targets for drug development. Many agents are under development and have begun to enter early and even later-stage clinical trials. Results of these agents have demonstrated some encouraging activity but in a small number of patients. Research into predictive biomarkers aims to select the patients who may benefit from these novel agents. This review will address several of these promising new agents, their potential relevance to CRC, results from early clinical studies, and their incorporation into future and ongoing CRC clinical trials. Clearly, there is an urgent need for new agents in this disease, but as we learned from the experience with epidermal growth factor receptor-targeted antibodies, patient selection will be increasingly be required for individualized therapy to become a reality in CRC.
KW - Metastatic colorectal cancer
KW - Novel agents
KW - Targeted agents
UR - http://www.scopus.com/inward/record.url?scp=77953648749&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953648749&partnerID=8YFLogxK
U2 - 10.1097/PPO.0b013e3181e076c5
DO - 10.1097/PPO.0b013e3181e076c5
M3 - Article
C2 - 20526106
AN - SCOPUS:77953648749
VL - 16
SP - 273
EP - 282
JO - Cancer journal (Sudbury, Mass.)
JF - Cancer journal (Sudbury, Mass.)
SN - 1528-9117
IS - 3
ER -